Use of a Modified α-N-Acetylgalactosaminidase in the Development of Enzyme Replacement Therapy for Fabry Disease

American Journal of Human Genetics

Volumn 85, Issue 5, 2009, Pages 569-580

  Tajima, Youichi ^a,b   Kawashima, Ikuo ^a,b   Tsukimura, Takahiro ^a,b   Sugawara, Kanako ^a   Kuroda, Mayuko ^a   Suzuki, Toshihiro ^a   Togawa, Tadayasu ^a   Chiba, Yasunori ^c   Jigami, Yoshifumi ^c   Ohno, Kazuki ^d   Fukushige, Tomoko ^e   Kanekura, Takuro ^e   Itoh, Kohji ^f   Ohashi, Toya ^g   Sakuraba, Hitoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d NPO for the Promotion of Research on Intellectual Property Tokyo   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f Graduate School of Pharmaceutical Sciences   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLUMBERLLIFERYL ALPHA DEXTRO GALACTOPYRANOSIDE; AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; ALPHA N ACETYLGALACTOSAMINIDASE; GLOBOTRIAOSYLCERAMIDE; MANNOSE 6 PHOSPHATE; MODIFIED ALPHA N ACETYLGALACTOSAMINIDASE; PYRANOSIDE; RECOMBINANT ENZYME; RETROVIRUS VECTOR; SOMATOMEDIN B RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS REACTION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFECT; DRUG PURIFICATION; DRUG SPECIFICITY; DRUG STABILITY; ENZYME MECHANISM; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FIBROBLAST CULTURE; HEART; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO GENE TRANSFER; KIDNEY; LIVER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PH; PLASMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; PROTEIN LOCALIZATION; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ALPHA-N-ACETYLGALACTOSAMINIDASE; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; CATALYSIS; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; DRUG STABILITY; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FIBROBLASTS; FLUORESCENT DYES; GALACTOSIDES; GENETIC VECTORS; HUMANS; HYDROGEN-ION CONCENTRATION; HYMECROMONE; IMMUNOHISTOCHEMISTRY; KIDNEY; LIVER; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR WEIGHT; MYOCARDIUM; RECOMBINANT PROTEINS; RETROVIRIDAE; TRANSFECTION; TRIHEXOSYLCERAMIDES;

CRICETULUS GRISEUS; MUS;

EID: 71849085606     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajhg.2009.09.016     Document Type: Article

References (40)

1. Desnick R.J., Ioannou Y.A., and Eng C.M. alpha-Galactosidase A deficiency: Fabry disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. Eighth Edition (2001), McGraw-Hill, New York, USA 3733-3774
2. Spada M., Paqgliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., and Desnick R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 79 (2006) 31-40
3. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68 (2001) 711-722
4. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 345 (2001) 9-16
5. Schiffmann R., Murray G.J., Treco D., Daniel P., Sellos-Moura M., Myers M., Quirk J.M., Zirzow G.C., Borowski M., Loveday K., et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. USA 97 (2000) 365-370
6. Kornfeld S., and Sly W.S. I-cell disease and pseudo-Hurler polydystrophy: Disorders of lysosomal enzyme phosphorylation and localization. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. Eighth Edition (2001), McGraw-Hill, New York 3469-3482
7. Sakuraba H., Murata-Ohsawa M., Kawashima I., Tajima Y., Kotani M., Ohshima T., Chiba Y., Takashiba M., Jigami Y., Fukushige T., et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J. Hum. Genet. 51 (2006) 180-188
8. Ohashi T., Sakuma M., Kitagawa T., Suzuki K., Ishige N., and Eto Y. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol. Genet. Metab. 92 (2007) 271-273
9. Ohashi T., Iizuka S., Ida H., and Eto Y. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol. Genet. Metab. 94 (2008) 313-318
10. Vedder A.C., Breunig F., Donker-Koopman W.E., Mills K., Young E., Winchester B., Ten Berge I.J., Groener J.E., Aerts J.M., Wanner C., et al. Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3. Mol. Genet. Metab. 94 (2008) 319-325
11. Dean K.J., and Sweeley C.C. Fabry disease: α-galactosidase A deficiency. In: Glew R.H., and Peters S.P. (Eds). Practical Enzymology of the Sphingolipidoses (1977), Alan R. Liss, New York 173-216
12. Petrey D., Xiang Z., Tang C.L., Xie L., Gimpelev M., Mitros T., Soto C.S., Goldsmith-Fischman S., Kernytsky A., Schlessinger A., et al. Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling. Proteins 53 (2003) 430-435
13. Garman S.C., Hannick L., Zhu A., and Garboczi D.N. The 1.9 Å structure of α-N-acetylgalactosaminidase: Molecular basis of glycosidase deficiency diseases. Structure 10 (2002) 425-434
14. Garman S.C., and Garboczi D.N. The molecular defect leading to Fabry disease: Structure of human alpha-galactosidase. J. Mol. Biol. 337 (2004) 319-335
15. Dudek M.J., and Ponder J.W. Accurate modeling of the intramolecular electrostatic energy of proteins. J. Comput. Chem. 16 (1995) 791-816
16. Kong M.J., and Ponder J.W. Calculation of the reaction field due to off-center point multipoles. J. Chem. Phys. 107 (1997) 481-492
17. Pappu R.V., Hart R.K., and Ponder J.W. Analysis and application of potential energy smoothing for global optimization. J. Phys. Chem. B 102 (1998) 9725-9742
18. Ren P., and Ponder J.W. Polarizable atomic multipole water model for molecular mechanics simulation. J. Phys. Chem. B 107 (2003) 5933-5947
19. Mayes J.S., Scheerer J.B., Sifers R.N., and Donaldson M.L. Differential assay for lysosomal α-galactosidases in human tissues and its application to Fabry's disease. Clin. Chim. Acta 112 (1981) 247-251
20. Hu P., Reuser A.J., Janse H.C., Kleijer W.J., Schindler D., Sakuraba H., Tsuji A., Suzuki Y., and van Diggelen O.P. Biosynthesis of human α-N-acetylgalactosaminidase: Defective phosphorylation and maturation in infantile α-NAGA deficiency. Biochem. Biophys. Res. Commun. 175 (1991) 1097-1103
21. Akagi T., Sasai K., and Hanafusa H. Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc. Natl. Acad. Sci. USA 100 (2003) 13567-13572
22. Swift S., Lorens J., Achacoso P., and Nolan G.P. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. In: Coligan J.E. (Ed). Current Protocols in Immunology (2001), John Wiley and Sons, New York 10.17.14-10.17.29
23. Okumiya T., Ishii S., Takenaka T., Kase R., Kamei S., Sakuraba H., and Suzuki Y. Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease. Biochem. Biophys. Res. Commun. 214 (1995) 1219-1224
24. Sakuraba H., Chiba Y., Kotani M., Kawashima I., Ohsawa M., Tajima Y., Takaoka Y., Jigami Y., Takahashi H., Hirai Y., et al. Corrective effect on Fabry mice of yeast recombinant human α-galactosidase with N-linked sugar chains suitable for lysosomal delivery. J. Hum. Genet. 51 (2006) 341-352
25. Sugawara K., Tajima Y., Kawashima I., Tsukimura T., Saito S., Ohno K., Iwamoto K., Kobayashi T., Itoh K., and Sakuraba H. Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. Mol. Genet. Metab. 96 (2009) 233-238
26. Ries M., Clarke J.T., Whybra C., Mehta A., Loveday K.S., Brady R.O., Beck M., and Schiffmann R. Enzyme replacement in Fabry disease: Pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents. J. Clin. Pharmacol. 47 (2007) 1222-1230
27. Kotani M., Kawashima I., Ozawa H., Ogura K., Ariga T., and Tai T. Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: Evidence for differential distribution of the glycolipids in rat small intestine. Arch. Biochem. Biophys. 310 (1994) 89-96
28. Ohshima T., Murray G.J., Swaim W.D., Longenecker G., Quirk J.M., Cardarelli C.O., Sugimoto Y., Pastan I., Gottesman M.M., Brady R.O., et al. alpha-Galactosidase A deficient mice: A model of Fabry disease. Proc. Natl. Acad. Sci. USA 94 (1997) 2540-2544
29. Ohshima T., Schiffmann R., Murray G.J., Kopp J., Quirk J.M., Stahl S., Chan C.-C., Zerfas P., Tao-Cheng J.-H., Ward J.M., et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl. Acad. Sci. USA 96 (1999) 6423-6427
30. Ioannou Y.A., Zeidner K.M., Gordon R.E., and Desnick R.J. Fabry disease: Preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 68 (2001) 14-25
31. Takahashi H., Hirai Y., Migita M., Seino Y., Fukuda Y., Sakuraba H., Kase R., Kobayashi T., Hashimoto Y., and Shimada T. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc. Natl. Acad. Sci. USA 99 (2002) 13777-13782
32. Linthorst G.E., Hollak C.E., Donker-Koopman W.E., Strijland A., and Aerts J.M. Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 66 (2004) 1589-1595
33. Bodensteiner D., Scott C.R., Sims K.B., Shepherd G.M., Cintron R.D., and Germain D.P. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet. Med. 10 (2008) 353-358
34. Desnick R.J., and Schindler D. alpha-N-Acetylgalactosaminidase deficiency: Schindler disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. Eighth Edition (2001), McGraw-Hill, New York 3483-3505
35. Beutler E., and Kuhl W. Purification and properties of human alpha-galactosidases. J. Biol. Chem. 247 (1972) 7195-7200
36. Schram A.W., Hamers M.N., and Tager J.M. The identity of alpha-galactosidase B from human liver. Biochim. Biophys. Acta 482 (1977) 138-144
37. Ohta M., Ohnishi T., Ioannou Y.A., Hodgson M.E., Matsuura F., and Desnick R.J. Human α-N-acetylgalactosaminidase: Site occupancy and structure of N-linked oligosaccharide. Glycobiology 10 (2000) 251-261
38. Chiba Y., Sakuraba H., Kotani M., Kase R., Kobayashi K., Takeuchi M., Ogasawara S., Maruyama Y., Nakajima T., Takaoka Y., et al. Production in yeast of α-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology 12 (2002) 821-828
39. Kawashima I., Watabe K., Tajima Y., Fukushige T., Kanzaki T., Kanekura T., Sugawara K., Ohyanagi N., Suzuki T., Togawa T., et al. Establishment of immortalized Schwann cells from Fabry mice and their low uptake of recombinant α-galactosidase. J. Hum. Genet. 52 (2007) 1018-1025
40. Sandhoff K., Kolter T., and Harzer K. Sphingolipid activator proteins. In: Scriver C.R., Beauded A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. Eighth Edition (2001), McGraw-Hill, New York 3371-3388